{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:14:58Z","timestamp":1785842098549,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SEMERGEN - Medicina de Familia"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.semerg.2017.04.010","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T23:45:12Z","timestamp":1495583112000},"page":"265-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Vacuna nonavalente frente al virus del papiloma humano. Actualizaci\u00f3n 2017"],"prefix":"10.1016","volume":"43","author":[{"given":"F.X.","family":"Bosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Torn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2017.04.010_bib0155","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30 Suppl 5","author":"Doorbar","year":"2012","journal-title":"Vaccine."},{"key":"10.1016\/j.semerg.2017.04.010_bib0160","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1586\/14760584.2015.1089174","article-title":"9-valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV","volume":"14","author":"Pitisuttithum","year":"2015","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.semerg.2017.04.010_bib0165","unstructured":"Documento de Consenso 2011 de Sociedades Cient\u00edficas Espa\u00f1olas. Vacunaci\u00f3n frente al virus del papiloma humano [consultado 12 Nov 2016]. Disponible en: http:\/\/vacunasaep.org\/sites\/vacunasaep.org\/files\/VPH_Consenso_Sociedades_2011.pdf"},{"key":"10.1016\/j.semerg.2017.04.010_bib0170","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pvr.2015.06.003","volume":"1","author":"Hartwig","year":"2015","journal-title":"Papillomavirus Res."},{"key":"10.1016\/j.semerg.2017.04.010_bib0175","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad (MSSSI). Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios (AEMPS). Centro de Informaci\u00f3n online de Medicamentos de la AEMPS\u2013CIMA [consultado 5 Oct 2016]. Disponible en: https:\/\/www.aemps.gob.es\/cima\/fichasTecnicas.do"},{"key":"10.1016\/j.semerg.2017.04.010_bib0180","unstructured":"Grupo de Trabajo VPH 2012 de la Ponencia de Programa y Registro de Vacunaciones. Revisi\u00f3n del programa de vacunaci\u00f3n frente a virus del papiloma humano en Espa\u00f1a. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, Servicios Sociales e Igualdad, 2013 [consultado 12 Nov 2016]. Disponible en: https:\/\/www.msssi.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/docs\/PapilomaVPH.pdf"},{"key":"10.1016\/j.semerg.2017.04.010_bib0185","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad (MSSSI). Calendarios de vacunaci\u00f3n [consultado 24 Ene 2017]. Disponible en: https:\/\/www.msssi.gob.es\/ciudadanos\/proteccionSalud\/vacunaciones\/docs\/CalendarioVacunacion2017.pdf"},{"key":"10.1016\/j.semerg.2017.04.010_bib0190","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad (MSSSI). Coberturas de vacunaci\u00f3n frente a virus del papiloma humano (VPH-pauta completa ni\u00f1as 11-14 a\u00f1os). Comunidades aut\u00f3nomas 2015 o curso escolar 2014-2015 [consultado 16 Nov 2016]. Disponible en: http:\/\/www.msssi.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/docs\/CoberturasVacunacion\/Tabla8.pdf"},{"key":"10.1016\/j.semerg.2017.04.010_bib0195","first-page":"1","article-title":"AEPCC-Gu\u00eda: Vacunaci\u00f3n selectiva frente al virus del papiloma humano en poblaciones de riesgo elevado","author":"Campins","year":"2016","journal-title":"Publicaciones AEPCC."},{"key":"10.1016\/j.semerg.2017.04.010_bib0200","unstructured":"Ficha t\u00e9cnica o resumen de las caracter\u00edsticas del producto. Gardasil 9\u00ae [consultado 11 Oct 2016]. Disponible en: http:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150610131761\/anx_131761_es.pdf"},{"key":"10.1016\/j.semerg.2017.04.010_bib0205","unstructured":"European Medicines Agency (EMA). Assesment history [consultado 12 Nov 2016]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation\/human\/003852\/WC500202890.pdf"},{"key":"10.1016\/j.semerg.2017.04.010_bib0210","unstructured":"European Medicines Agency (EMA). European public assesment report [consultado 11 Oct 2016]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003852\/WC500189113.pdf"},{"key":"10.1016\/j.semerg.2017.04.010_bib0215","first-page":"465","article-title":"Human papillomavirus vaccines: WHO position paper, October 2014","volume":"89","author":"World Health Organization (WHO)","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.semerg.2017.04.010_bib0220","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2017.04.010_bib0225","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1016\/j.vaccine.2016.06.056","article-title":"A phase iii clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men","volume":"34","author":"Van Damme","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.semerg.2017.04.010_bib0230","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/INF.0000000000000773","article-title":"A randomized, double-blind, phase iii study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil\u00ae in 9-15-year-old girls","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.semerg.2017.04.010_bib0235","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1016\/j.vaccine.2015.06.088","article-title":"Immunogenicity and safety of the 9-valent HPV vaccine in men","volume":"33","author":"Castellsagu\u00e9","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.semerg.2017.04.010_bib0240","unstructured":"Ficha t\u00e9cnica o resumen de las caracter\u00edsticas del producto. Gardasil [consultado 11 Oct 2016]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000703\/WC500021142.pdf"},{"key":"10.1016\/j.semerg.2017.04.010_bib0245","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-4387","article-title":"Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials","volume":"138","author":"Moreira","year":"2016","journal-title":"Pediatrics."},{"key":"10.1016\/j.semerg.2017.04.010_bib0250","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/INF.0000000000000694","article-title":"An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age","volume":"34","author":"Kosalaraksa","year":"2015","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.semerg.2017.04.010_bib0255","unstructured":"Comit\u00e9 Asesor de Vacunas de la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Coadministraci\u00f3n de las vacunas entre s\u00ed y con otros productos biol\u00f3gicos. En: Manual de Vacunas en l\u00ednea del CAV de la AEP [consultado 18 Nov 2016]. Disponible en: http:\/\/vacunasaep.org\/documentos\/manual\/cap-2"},{"key":"10.1016\/j.semerg.2017.04.010_bib0260","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1542\/peds.2014-4199","article-title":"Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines","volume":"136","author":"Schilling","year":"2015","journal-title":"Pediatrics."},{"key":"10.1016\/j.semerg.2017.04.010_bib0265","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.semerg.2017.04.010_bib0270","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1016\/j.vaccine.2016.07.035","article-title":"Corrigendum to \u201cUse of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines\u201d [Vaccine 34 (2016) 757-761]","volume":"34","author":"Van Damme","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.semerg.2017.04.010_bib0275","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol Oncol."},{"issue":"Supl 1","key":"10.1016\/j.semerg.2017.04.010_bib0280","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0304-5013(12)73065-0","article-title":"Vacunaci\u00f3n frente al c\u00e1ncer de c\u00e9rvix en mujeres fuera de los programas de vacunaci\u00f3n sistem\u00e1tica, con o sin infecci\u00f3n por el virus del papiloma humano o lesi\u00f3n cervical. Encuesta de opini\u00f3n y recomendaciones","volume":"55","author":"Torn\u00e9 Blad\u00e9","year":"2012","journal-title":"Prog Obstet Ginecol."},{"key":"10.1016\/j.semerg.2017.04.010_bib0285","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMoa1612296","article-title":"Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes","volume":"376","author":"Scheller","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2017.04.010_bib0290","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrclinonc.2015.146","article-title":"HPV-FASTER: Broadening the scope for prevention of HPV-related cancer","volume":"13","author":"Bosch","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.semerg.2017.04.010_bib0295","unstructured":"Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) presentation slides: June 2016 Meeting. HPV vaccine availability, United States [consultado 24 Oct 2016]. Disponible en: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/slides-2016-06.html"},{"key":"10.1016\/j.semerg.2017.04.010_bib0300","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination \u2014 Updated recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep."}],"container-title":["SEMERGEN - Medicina de Familia"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359317301168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359317301168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T14:22:47Z","timestamp":1535811767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359317301168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1138359317301168"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2017.04.010","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vacuna nonavalente frente al virus del papiloma humano. Actualizaci\u00f3n 2017","name":"articletitle","label":"Article Title"},{"value":"SEMERGEN - Medicina de Familia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2017.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}